Kiniksa Pharmaceuticals International, plc (KNSA)
| Market Cap | 4.10B +110.1% |
| Revenue (ttm) | 754.05M +56.7% |
| Net Income | 73.06M |
| EPS | 0.91 |
| Shares Out | 76.94M |
| PE Ratio | 58.66 |
| Forward PE | 42.00 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 383,821 |
| Open | 53.48 |
| Previous Close | 53.65 |
| Day's Range | 53.02 - 55.08 |
| 52-Week Range | 25.70 - 59.87 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 63.50 (+19.27%) |
| Earnings Date | Apr 28, 2026 |
About KNSA
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericard... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for KNSA stock is "Strong Buy." The 12-month stock price target is $63.5, which is an increase of 19.27% from the latest price.
News
Kiniksa price target raised to $64 from $62 at Canaccord
Canaccord raised the firm’s price target on Kiniksa (KNSA) to $64 from $62 and keeps a Buy rating on the shares. The firm noted Kiniksa reported 1Q26 earnings. Top-line revenue…
Kiniksa price target raised to $59 from $58 at Wedbush
Wedbush raised the firm’s price target on Kiniksa (KNSA) to $59 from $58 and keeps an Outperform rating on the shares. The firm notes Q1 Arcalyst revenue of $214.3M beat…
Kiniksa price target raised to $60 from $50 at Citi
Citi raised the firm’s price target on Kiniksa (KNSA) to $60 from $50 and keeps a Buy rating on the shares.
Kiniksa price target raised to $71 from $58 at Jefferies
Jefferies analyst Roger Song raised the firm’s price target on Kiniksa (KNSA) to $71 from $58 and keeps a Buy rating on the shares after a “beat-and-raise” Q1 report. Management…
Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q1 2026
Q1 2026 saw ARCALYST revenue rise 56% year-over-year to $214.3M, driving net income to $22.6M and prompting a raised full-year revenue outlook. Strong commercial execution, new prescriber growth, and targeted DTC campaigns support continued momentum.
Kiniksa Pharmaceuticals International, Earnings release: Q1 2026
Kiniksa Pharmaceuticals International, released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Kiniksa Pharmaceuticals International, Slides: Q1 2026
Kiniksa Pharmaceuticals International, has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Kiniksa Pharmaceuticals International, Quarterly report: Q1 2026
Kiniksa Pharmaceuticals International, has published its Q1 2026 quarterly earnings report on April 28, 2026.
Kiniksa reports Q1 EPS 27c, consensus 16c
Reports Q1 revenue $214.27M, consensus $206.09M. “Five years from launch, Kiniksa (KNSA) continues to deliver strong ARCALYST revenue growth, driven by expanding adoption of IL-1alpha and IL-1beta inh...
Kiniksa raises FY26 revenue view to $930M-$945M from $900M-$920M
Consensus $913.27M. The company said, “Kiniksa (KNSA) expects 2026 ARCALYST net product revenue of between $930 million and $945 million, compared to prior guidance of between $900 million and $920…
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
– ARCALYST ® (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-...
Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at ...
Kiniksa price target raised to $58 from $53 at Wedbush
Wedbush raised the firm’s price target on Kiniksa (KNSA) to $58 from $53 and keeps an Outperform rating on the shares. The firm notes Arcalyst heads into Q1 earnings with…
Kiniksa Pharmaceuticals International, Proxy statement: Proxy filing
Kiniksa Pharmaceuticals International, filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Kiniksa Pharmaceuticals International, Proxy statement: Proxy filing
Kiniksa Pharmaceuticals International, filed a proxy statement on April 16, 2026, providing details for shareholder voting and corporate governance matters.
Kiniksa launches direct-to-consumer campaign for Arcalyst
Kiniksa (KNSA) announced the launch of Heart’s Home, a direct-to-consumer campaign for Arcalyst, the FDA approved therapy for recurrent pericarditis. This multi-faceted campaign is aimed at identifyin...
Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis
– Educational campaign to raise awareness of recurrent pericarditis and to empower patients to discuss ARCALYST with their healthcare provider – – Media accompanying this announcement is available by ...
Kiniksa Pharmaceuticals International, Transcript: TD Cowen 46th Annual Health Care Conference
Strong revenue growth in 2025 was driven by increased patient numbers, prescriber engagement, and longer therapy duration, with significant market opportunity remaining. Pipeline progress includes upcoming Phase II data for KPL-387 and ongoing development of KPL-1161, supported by robust cash flow and a disciplined approach to expansion.
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the TD Cowen 46th Annual Heal...
Kiniksa price target raised to $53 from $50 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Kiniksa (KNSA) to $53 from $50 and keeps an Outperform rating on the shares. The firm notes Arcalyst net product…
Kiniksa price target raised to $53 from $50 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Kiniksa (KNSA) to $53 from $50 and keeps an Outperform rating on the shares. The firm notes Arcalyst net product…
Kiniksa Pharmaceuticals International, Earnings Call Transcript: Q4 2025
ARCALYST revenue surged 62% year-over-year to $677.6 million in 2025, with net income turning positive and strong cash generation. Pipeline progress continues with KPL-387 and KPL-1161, and 2026 revenue guidance is set at $900–$920 million.
Kiniksa Pharmaceuticals International, Annual report: Q4 2025
Kiniksa Pharmaceuticals International, has published its Q4 2025 annual report on February 24, 2026.